Novo Nordisk says Wegovy helped obese children lose weight in trial
Novo Nordisk said its Wegovy injection helped children with obesity shed weight in a clinical trial; two out of five participants were no longer classified after 68 weeks.
Story updates
10:45:15 AM UTC
SquawkNews
Novo Nordisk OMXCOP:NOVO_B said on Monday that in a late-stage trial, 40.4% of children aged 6 to under 12 treated with semaglutide, the active ingredient in its blockbuster weight-loss drug Wegovy, were no longer classified as having obesity after 68 weeks, assuming full adherence to the treatment.
4% of children aged 6 to under 12 treated with semaglutide, the active ingredient in its blockbuster weight-loss drug Wegovy, were no longer classified as having obesity after 68 weeks, assuming full adherence to the treatment.